N.E.W. Community Clinic opens new location for behavioral health care service in Green Bay
The NEW Community Clinic now has a spot for behavioral health at 424 South Monroe Avenue in Green Bay, providing in-depth care for people at least four years old.
The Weidner announces seven show lineup for 2025-26 Broadway In Green Bay
The providers at this new location, according to the NEW Community Clinic website, are all trained in various forms of mental health care at all ages, from children to teens to adults.
The central issues vary:
Anxiety
Cognitive decline
Grief
Anger
Attention issues
Stress
The services vary from outpatient therapy, couples/family therapy and psychiatric medication management. This marks the third NEW Community Clinic designed to focus on mental health.
In a release following the ribbon cutting, Dr. Katie Patterson, NEW Community Clinic's behavioral health director, expressed her excitement for the new clinic and what it means.
Victory II Cruise returns to Green Bay after two year absence, marks 2025's first docking
'This is an exciting day for the community as we expand the ability to provide services to those with limited or no access to the support they need,' Dr. Patterson said via the release. 'Our approach is client-centered, and we aim to meet people where they are and share the tools they need to heal and improve their health and wellbeing.'
More information is available on the NEW Community Clinic website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
2 hours ago
- New York Times
U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS
The federal program to combat H.I.V. in developing nations earned a reprieve last week when Congress voted to restore $400 million in funding. Still, officials at the State Department have been mapping out a plan to shut it down in the coming years. Planning documents for the President's Emergency Plan for AIDS Relief, obtained by The New York Times, call for the organization to set a new course that focuses on 'transitioning' countries away from U.S. assistance, some in as little as two years. PEPFAR, as the program is called, would cease to exist as an initiative to provide medicines and services needed to treat and prevent the spread of H.I.V. in low-income countries. It would be replaced by 'bilateral relationships' with low-income countries focused on the detection of outbreaks that could threaten the United States and the creation of new markets for American drugs and technologies, according to the documents. 'With targeted investment, PEPFAR's H.I.V. control capabilities in these countries could be transformed into a platform for rapid detection and outbreak response to protect Americans from disease threats like Ebola,' the plan says. A State Department spokeswoman said the document had not been finalized. 'The referenced document is not reflective of the State Department's policy on PEPFAR and was never cleared by Department leadership,' she said. Want all of The Times? Subscribe.
New York Times
16 hours ago
- New York Times
Corrections: July 23, 2025
An article on Sunday about the legal implications of being an organ donor misstated the number of Americans who are in the national donor registry. There are more than 173 million Americans in both state registries and the national registry, not the national registry alone. An article on Monday about the biotech company Sarepta Therapeutics and its distribution of a treatment for a deadly muscle-wasting disease misstated the date that Sarepta halted shipments of Elevidys for non-ambulatory Duchenne patients. Shipments were halted on June 15, not July 15. An article on Tuesday about President Trump urging two professional sports teams to change their names misstated the number of carved figures, known as the Guardians of Traffic, on the Hope Memorial Bridge in Cleveland. There are eight, not two. An obituary on Tuesday about the actor Kenneth Colley misstated the cause of the character Admiral Piett's death in the movie 'Return of the Jedi.' His ship crashes into the Death Star; he is not shot down by a Rebel fighter. Errors are corrected during the press run whenever possible, so some errors noted here may not have appeared in all editions. To contact the newsroom regarding correction requests, please email nytnews@ To share feedback, please visit Comments on opinion articles may be emailed to letters@ For newspaper delivery questions: 1-800-NYTIMES (1-800-698-4637) or email customercare@
Yahoo
a day ago
- Yahoo
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th – NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present full data from the prespecified Alzheimer's Disease (AD) biomarker analyses in the BROADWAY clinical trial (NCT05142722) in a late-breaking oral presentation at the Alzheimer's Association International Conference (AAIC), being held July 30, 2025 in Toronto, Canada. Details of the presentation are as follows: Presentation Title: Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with Cardiovascular DiseaseSession Title: Developing Topics on Innovative Therapeutic ApproachesPresentation Date and Time: Wednesday, July 30, 2025, 8:21-8:28 AM ETPresenter: Philip Scheltens M.D., Room 718 Conference Call and Webcast Information NewAmsterdam will host a live webcast and conference call at 10:00 a.m. ET on July 30, 2025 to review the full AD biomarker data presented at AAIC. The call will include remarks from featured speakers including: Philip Scheltens, M.D., Ph.D., professor of Neurology at the Vrije Universiteit Amsterdam and partner and head of EQT Life Sciences Dementia Fund; Kellyann Niotis, M.D., director of Parkinson's and Lewy Body Dementia Research at The Institute for Neurogenerative Diseases - Parkinson's and Alzheimer's Research Education Foundation; and Nathaniel Chin, M.D., medical director and Clinical Core Co-Leader for the Wisconsin Alzheimer's Disease Research Center (ADRC) and medical director for the Wisconsin Registry for Alzheimer's Prevention (WRAP). To access the live webcast, participants may register here. The live webcast will be available under the 'Events & Presentations' section of the Investor Relations page of the Company's website at To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived replay of the webcast will be available on NewAmsterdam's website following the live event. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactReal Chemistry on behalf of NewAmsterdamChristian EdgingtonP: 1-513-310-6410cedgington@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
